Low molecular weight dextran infusions.

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Failure of low molecular weight dextran infusions in scleroderma.

Of the many treatments used in scleroderma (progressive systemic sclerosis), none has so far been shown to alter the fundamental course of the disease (see review Bywaters and Scott, 1965). Although corticosteroids may give symptomatic benefit in the early stages (Rodnan, Black, Bollet, and Bunim, 1956), prolonged therapy is unrewarding (Zion, Goldberg, and Suzman, 1955). Several other promisin...

متن کامل

Low molecular weight dextran in experimental embolectomy.

The canine middle cerebral artery (MCA) was embolized with a pliable cylinder 8 mm long by 1.6 mm in diameter via the internal carotid artery. Both control and experimental embolectomies were performed 6 hours following embolization. The experimental animals were treated with low molecular weight dextran (LMD). In the control animals, the average volume of infarction in the brain was 1.45 cm.3 ...

متن کامل

Low molecular weight gelator-dextran composites.

Incorporation of dextran into a hydrogel formed using a low molecular weight dipeptide-conjugate gelator results in controlled modification of the material properties.

متن کامل

Low-molecular-weight dextran in acute myocardial infarction.

In spite of vasopressor agents, anti-arrhythmic drugs, early ambulation, and anticoagulant therapy the mortality among patients with acute myocardial infarction is almost 40%/,O . Intensive-care units may reduce this figure, but other attempts to lower the mortality should be sought. Langsjoen et al. (1963) reported the beneficial effect of low-molecular-weight dextran (mean molecular weight 40...

متن کامل

Renal failure associated with low-molecular-weight dextran infusion.

It is suggested that this preparation should be tried in every case where artificial pacemaking is to be considered or has failed, except in patients who have shown ventricular tachycardia or ventricular fibrillation. The need for close observation during the trial stage is stressed and the dosage scheme used is outlined. Side-effects, which were few in this series, are described. Sudden withdr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: BMJ

سال: 1971

ISSN: 0959-8138,1468-5833

DOI: 10.1136/bmj.2.5753.109